Sugi Predict

Sugi Predict / Targets / PRKDC

PRKDC

DNA-dependent protein kinase catalytic subunit · P78527 · PRKDC on Sugi Atlas →

191,306 patent compounds predicted against PRKDC, 70,732 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL129599 SCHEMBL129599 0.59 19/20
Ly-294002 Ly-294002 (SCHEMBL94377) 1.00 18/20
SCHEMBL129826 SCHEMBL129826 0.60 18/20
SCHEMBL12162 SCHEMBL12162 0.74 17/20
SCHEMBL129501 SCHEMBL129501 0.65 17/20
SCHEMBL129811 SCHEMBL129811 0.63 17/20
SCHEMBL129822 SCHEMBL129822 0.63 17/20
SCHEMBL129595 SCHEMBL129595 0.62 17/20
SCHEMBL129581 SCHEMBL129581 0.59 17/20
SCHEMBL11807 SCHEMBL11807 0.59 16/20
SCHEMBL10811 SCHEMBL10811 0.57 16/20
SCHEMBL129512 SCHEMBL129512 0.56 16/20
SCHEMBL129575 SCHEMBL129575 0.49 16/20
SCHEMBL129865 SCHEMBL129865 0.67 15/20
SCHEMBL128512 SCHEMBL128512 0.60 15/20
SCHEMBL12282 SCHEMBL12282 0.59 15/20
SCHEMBL129616 SCHEMBL129616 0.51 15/20
SCHEMBL129613 SCHEMBL129613 0.50 15/20
SCHEMBL128499 SCHEMBL128499 0.71 14/20
SCHEMBL129578 SCHEMBL129578 0.67 14/20

Clinical trials — most relevant to PRKDC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Epidermal Growth Factor Receptor Inhibition for Keratinopathies PHASE1/PHASE2NOT_YET_RECRUITING
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study PHASE2UNKNOWN
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study PHASE2COMPLETED
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma PHASE2COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases PHASE1COMPLETED
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex nanCOMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
IL-17 Role in Variants of Psoriasis nanCOMPLETED
Exome Evaluation in Patients Living With Diabetes Complicated by Charcot Neuroarthropathy. nanCOMPLETED
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Immune Signature of Palmoplantar Pustulosis nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PRKDC binder may also engage these)

ProteinNameSimilarity
P97313 — 1.000 P97313 →
Q9DEI1 — 1.000 Q9DEI1 →
Q8WN22 — 1.000 Q8WN22 →
Q8QGX4 — 0.999 Q8QGX4 →
E9PVA8 — 0.996 E9PVA8 →
Q5XG71 — 0.995 Q5XG71 →
GCN1 Stalled ribosome sensor GCN1 0.995 landscape →
Q8BKX6 — 0.994 Q8BKX6 →
E1C231 — 0.994 E1C231 →
Q8H0T4 — 0.993 Q8H0T4 →
Q8BH53 — 0.993 Q8BH53 →
F4IP13 — 0.993 F4IP13 →
P42173 — 0.993 P42173 →
Q5WNI9 — 0.993 Q5WNI9 →
SMG1 Serine/threonine-protein kinase SMG1 0.992 landscape →
A8WTE8 — 0.992 A8WTE8 →
Q61037 — 0.992 Q61037 →
O74447 — 0.992 O74447 →
Q8IGJ0 — 0.992 Q8IGJ0 →
HEATR1 HEAT repeat-containing protein 1 0.992 landscape →
Q6PR54 — 0.992 Q6PR54 →
F6S215 — 0.992 F6S215 →
Q14156 — 0.992 Q14156 →
Q6PQD5 — 0.992 Q6PQD5 →
Q6DFV1 — 0.992 Q6DFV1 →
Q6A009 — 0.992 Q6A009 →
B0CM26 — 0.992 B0CM26 →
PI4KA Phosphatidylinositol 4-kinase alpha 0.992 landscape →
Q9XW10 — 0.992 Q9XW10 →
F4I893 — 0.991 F4I893 →